Studies from this and other laboratories have demonstrated the ability of cefoxitin, a relatively new semisynthetic cephamycin, to antagonize the in vitro activity of a wide range of betalactam antibiotics (2, 3, 6-9, 14, 15, 17) . Recently, Kuck et al. have shown that such antagonisms also occur in vivo (9) . However, important questions still remain regarding the relationship of these in vitro antagonisms to the outcome of therapy when cefoxitin is used with another beta-lactam antibiotic. Therefore, the current study was designed to assess the therapeutic efficacy of drug combinations clearly shown to be antagonistic by in vitro disk approximation tests (6, 14, 15) . Since the preceding in vitro study had shown that antagonism may occur by at least two different mechanisms (15) , the strains and drugs selected for this study were those that appeared to involve different mechanisms. Cefamandole was chosen for study as it represented a beta-lactam antagonized by cefoxitin via the induction of drug-inactivating enzymes. Carbenicillin was chosen for study as it represented a beta-lactam antagonized by cefoxitin via the induction of drug-binding (but not inactivating) enzymes that create a barrier to target proteins. Enterobacter cloacae and Pseudomonas aeruginosa were selected because both species characteristically possess inducible beta-lactamases (12, 16) . Both mechanisms of antagonism appear operative in Enterobacter spp., whereas the barrier mechanism appears to be of primary importance in Pseudomonas spp. (15) . Since the in vitro study indicated that antagonism by both mechanisms involved the reversible induction of beta-lactamases, the ability of cefoxitin to antagonize the therapeutic efficacy of carbenicillin and cefamandole was assessed when (i) the drugs were administered simultaneously and (ii) cefoxitin was administered first so as to allow induction before exposure of the cells to the second drug.
MATERIALS AND METHODS
Bacterit strains. Two challenge strains of clinical origin were used: (i) E. cloacae susceptible in vitro to cefamandole and carbenicillin (minimal inhibitory concentration [MIC], 3.1 ,ug/ml), but resistant to cefoxitin (MIC, >50 ,ug/ml); and (ii) P. aeruginosa susceptible in vitro to carbenicillin (MIC, 50 ,ug/ml), but resistant to both cefamandole and cefoxitin. In vitro antagonism assays were performed by a disk approximation procedure described previously (14) . Beta-lactamase assays were performed as described in the preceding paper (15) .
Infection-treatment protocols. Experimental infections were induced as described previously (4 protective drug intramuscularly into separate leg muscles at 1 and 3.5 h postchallenge, or (ii) pretreatment of infected animals with cefoxitin (intramuscularly), at the time of challenge, followed by the protective drug (administered intramuscularly) at 1 and 3.5 h postchallenge. For all treatment regimens, the PD50 was determined by log-probit plot, and the 95% confidence levels were calculated (10) .
Postinfection recovery and analysis of challenge bacteria. For all animals dying within 48 h postinfection, isolates of the challenge strain were cultured from heart blood as described previously (4) and tested by dilution assay in Mueller-Hinton broth (MHB; inoculum, 105 colony-forming units per ml) for susceptibility to the protective drug used in treatment. For cefamandole and carbenicillin, E. cloacae isolates were considered resistant if the MIC of the drug was -25 ,g/ml.
In one experiment, animals were challenged with E. cloacae and treated with 25 mg of cefoxitin per kg at time of challenge. At 1 and 3.5 h postchallenge, cefamandole was administered at a dose of 100 mg/kg. Controls consisted of untreated animals, animals treated with cefoxitin alone, and animals treated with cefamandole alone. At 0.5-h intervals from 0.5 to 6.5 h postchallenge, two animals from each treatment and control group were sacrificed, and heart blood was removed. The heart blood was serially 10-fold diluted in saline and inoculated into Mueller-Hinton agar (MHA) and MHA containing 500 ,ug of cefamandole per ml to quantify challenge bacteria and to screen for emergence of cefamandole resistance, respectively. All results shown are averages of duplicate counts performed on heart blood from two animals.
RESULTS
Effect of cefoxitin on the PD50 of beta-lactamns. In vitro disk approximation tests with E. cloacae indicated that the activity of cefamandole and carbenicillin was antagonized by cefoxitin. Assays for beta-lactamases revealed the presence of cefoxitin-inducible enzymes in this strain capable of inactivating cefamandole but not carbenicillin (Table 1) . As shown in Table 2 , a PDo of cefoxitin was able to antagonize the in vivo efficacy of both cefamandole and carbenicillin in animals challenged with this bacterium. The antagonism was most pronounced with carbenicillin when either the simultaneous administration of cefoxitin and carbenicillin or single-dose cefoxitin pretreatment resulted in significantly decreased protection. With both carbenicillin and cefamandole, the greatest antagonism was observed with the single-dose cefoxitin pretreatment regimen.
Similar results were obtained in experiments with mice challenged with P. aeruginosa (Table   3 ). Again, in vitro disk approximation tests were predictive of in vivo outcome, and cefoxitininducible enzymes were demonstrable in the strain (Table 1) . In contrast to E. cloacae, antagonism was statistically significant when both the protective and antagonizing drugs were administered simultaneously. Although P. aeruginosa was resistant in vitro to cefamandole, as well as to cefoxitin, substitution of cefamandole for cefoxitin in the simultaneous treatment regimen produced no significant effect on the efficacy of carbenicillin (Table 3) . No antagonism between cefamandole and carbenicillin was seen in disk approximation assays.
Postinfection analysis of therapy. In experiments with both E. cloacae and P. aeruginosa, challenge bacteria were recovered from the heart blood of nonsurviving animals and tested for their susceptibility to the protective drug used in treatment. As shown in Table 4 , cefamandole-resistant isolates were recovered from dead animals in all treatment and control groups. The occurrence of such resistance was minimal (<20%) in untreated control animals and animals receiving only cefoxitin either at challenge or 1 and 3.5 h postinfection. However, animals treated with either regimen of cefoxitin plus cefamandole were less likely to harbor cefamandoleresistant isolates than were animals treated with cefamandole alone.
In cefoxitin-carbenicillin experiments with E cloacae ( Heart blood from 161 animals infected with P. aeruginosa was examined for carbenicillin-resistant isolates. No resistant isolates were detected among untreated animals or those treated with cefoxitin or carbenicillin, alone or in combination.
The degree of bacteremia in animals infected with E. cloacae, pretreated with cefoxitin, and then treated with cefamandole was determined at 0.5 h-intervals after infection. As shown in Fig. 1 , animals receiving only a single dose of cefoxitin at challenge were essentially the same as untreated controls and exhibited steadily increasing bacteremia. Animals receiving cefamandole at 1 and 3.5 h postinfection showed a reduction in the degree of bacteremia after both injections. The antagonistic effect of cefoxitin on cefamandole was reflected by a lack of welldefined reductions in bacterial blood counts after cefamandole administration. Cefamandoleresistant bacteria were cultured from only four animals during the experiment. Three of the animals received only cefamandole, and one was an untreated control (Fig. 1) . DISCUSSION The ability of cefoxitin to antagonize the efficacy of cefamandole and carbenicillin was demonstrated in animal infection models utilizing two different treatment regimens. These antagonisms confirmed and expanded the observations made in the preceding in vitro study (15) . First, disk approximation tests indicating antagonism were predictive of antagonism in vivo. Second, the ability of cefoxitin to antagonize the protective drug either when administered simultaneously with or before the protective drug provided further support for the mechanisms proposed previously. These mechanisms involved the induction of beta-lactamases that either inactivated the protective drug or created a barrier to target proteins. If such mechanisms had been operative in vivo, pretreatment or simultaneous treatment with cefoxitin or both should have been antagonistic. Such antagonism was observed, and both challenge strains possessed cefoxitin-inducible enzymes.
Analysis of the emergence of resistance to the protective drug also provided evidence that the in vivo antagonisms were due to a reversible induction process. In no instance were challenge isolates resistant to carbenicillin or cefamandole recovered more frequently from animals treated with cefoxitin, either alone or in combination with the protective drug. In fact, cefoxitin treatment reduced the incidence of cefamandole resistance in animals infected with E. cloacae. Since this analysis was performed on challenge isolates recovered from heart blood of animals dying after therapy, these results indicated that failure of cefamandole therapy in animals treated with cefamandole alone was due primarily to the in vivo emergence of resistance to this drug. Such resistance has been observed previously in other animal infection models (5, 11) and has recently been reported to occur in humans treated with cefamandole (1, 13). This in vivo development of resistance among Enterobacter spp. appears to be due to the selection of mutants producing high levels of beta-lactamase and occurs most frequently with strains possessing cefoxitin-inducible enzymes (13 
